Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oklahoma Acquires New Imaging Technology

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Protea Biosciences have announced that the University of Oklahoma’s Institute for Natural Products Applications and Research Technologies (INPART) has acquired the LAESI DP1000 biomolecular imaging system.

INPART is directed by Robert Cichewicz, PhD., associate professor in the Department of Chemistry and Biochemistry. The instrument will be used for the Institute’s natural products-based drug discovery operations. 

Cichewicz will be using this new instrument to characterize newly discovered compounds produced by fungi and other microbes, in an effort to develop new treatments for life-threatening infections. LAESI (short for Laser Ablation Electrospray Ionization) is designed to rapidly generate imaging profiles of the biomolecules present in cells and to analyze tissue sections identical to those used in pathology. The LAESI DP-1000 is intended to allow the direct identification of biomolecules in living cells and bacterial colonies, with analysis completed in seconds to minutes. Thus, molecular changes that occur in cells over time can be identified and tracked. 

Cichewicz said, “This instrument is designed to allow us to examine the changes that occur in fungal and bacterial colonies such as their production of secondary metabolites, permitting us to identify and characterize new candidate antimicrobial compounds.” 

Cichewicz’s laboratory studies microbial natural products, which are the unique compounds produced by fungi and bacteria. These compounds play important roles in helping microorganisms adapt to their environment, and they exhibit a diverse array of novel structures. The Cichewicz Laboratory focuses on using secondary metabolites from fungi and bacteria for the treatment of human diseases such as life-threatening infections and cancer. 

The LAESI DP1000, developed by Protea Biosciences, was selected by an independent judging panel and the editors of R&D Magazine to receive a prestigious 2012 R&D 100 Award, as one of the 100 most technologically significant products introduced in the past year. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protea Announces License Agreement with Yale
Company has announced an exclusive license agreement with Yale for new technology for detecting malignant melanoma skin cancer.
Tuesday, April 26, 2016
Protea, MSK, Dana-Farber Enter Collaborative Research Agreement
Protea's LAESI technology to be used to profile cancer cells to improve diagnosis and treatment selection
Wednesday, April 30, 2014
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
New Mechanism to Control Human Viral Infections Discovered
Researchers discover long sought after mechanism in human cells that could help treat diseases caused by viruses.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
New Strategy May Drop Cancer’s Guard
Scientists eye ways to deconstruct tumors’ protective wall with current diabetes drug.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!